Search Results
Dr. Kumar Discusses MLN9708 and Bortezomib in Multiple Myeloma
Dr. Kumar on a MLN9708 in Patients With Relapsed MM Not Refractory to Bortezomib
Dr. Kumar on Implications of BELLINI Trial in R/R Multiple Myeloma
Dr. Kumar on the Design of a Phase II Trial Looking at MLN9708
Dr. Kumar on Tourmaline-MM1 Study for Multiple Myeloma
Selinexor, bortezomib and dexamethasone shows PFS benefit for multiple myeloma
Dr. Kumar on Treatment Discontinuation in the ENDURANCE Myeloma Trial
OPTIMAL: bortezomib-based therapy vs thalidomide-based therapy in myeloma with renal failure
Dr Shaji Kumar Discusses Biological Foundations of New Multiple Myeloma Research
Dose reduction of selinexor in combination with bortezomib and dexamethasone in multiple myeloma
Bortezomib (Velcade) - Uses, Dosing, Side Effects | Pharmacist Review
Transitioning from bortezomib to ixazomib in patients with multiple myeloma
